<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Free radicals are known to activate coagulation and inhibit fibrinolysis </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="31530">Edaravone</z:chebi>, a free radical scavenger, protects vascular endothelial cells and neurons during <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> in in vitro models </plain></SENT>
<SENT sid="2" pm="."><plain>Hemorrhagic transformation and treatment outcomes were retrospectively examined in 76 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> cardiogenic embolism treated with <z:chebi fb="0" ids="31530">edaravone</z:chebi> in addition to routine treatment within 24 hours of the <z:hpo ids='HP_0003674'>onset</z:hpo> of symptoms </plain></SENT>
<SENT sid="3" pm="."><plain>Hemorrhagic transformation was categorized according to European Cooperative <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:hpo ids='HP_0001297'>Stroke</z:hpo> Study-II </plain></SENT>
<SENT sid="4" pm="."><plain>Patient characteristics were also evaluated, including evidence of <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo>, <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e>, history of smoking, National Institutes of Health <z:hpo ids='HP_0001297'>Stroke</z:hpo> Scale on arrival, and modified Rankin scale at 3 months post-<z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="31530">Edaravone</z:chebi> administration was one of the factors that contributed to increased frequency of hemorrhagic transformation, but had showed no significant relationship with the outcome </plain></SENT>
<SENT sid="6" pm="."><plain>The present study showed that <z:chebi fb="0" ids="31530">edaravone</z:chebi> administration increased the frequency of hemorrhagic transformation with <z:chebi fb="5" ids="28304">heparin</z:chebi> in patients with cardiogenic embolism </plain></SENT>
<SENT sid="7" pm="."><plain>Free radical scavenging may have promoted the coagulating conditions </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="31530">Edaravone</z:chebi> administration may allow reduction of the dose of <z:chebi fb="5" ids="28304">heparin</z:chebi> and tissue plasminogen activator in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>